TELUS Expands Into UAE AI Health Tech As Valuation Signals Upside Potential

• TELUS Health has entered an agreement with Abu Dhabi Health Data Services to provide AI driven personalized employee wellbeing solutions in the UAE.
• The collaboration includes one of the largest employee assistance programs in the UAE and is aimed at developing next generation AI healthcare tools.
• The announcement highlights TELUS’s global digital health ambitions and extends its footprint into the Middle Eastern healthcare technology market.

For investors watching TSX:T, this move adds an international healthcare technology angle to a company better known for its telecom roots. TELUS shares last closed at CA$19.42, with a return of 7.9% year to date and 4.5% over the past 30 days, while the 3 year and 5 year returns of 13.0% and 1.8% declines show a mixed longer term picture. This new partnership gives investors another concrete development to weigh alongside that track record.

Looking ahead, this UAE agreement could be a reference point for how TELUS builds out its health focused business outside Canada. Investors can watch for follow on contracts, product launches, or customer traction updates tied to this deal as possible indicators of how central AI driven healthcare becomes to the broader TELUS story.

Stay updated on the most important news stories for TELUS by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on TELUS.

3 things going right for TELUS that this headline doesn’t cover.

Quick Assessment

• ✅ Price vs Analyst Target: TELUS trades at CA$19.42 versus an analyst price target of CA$21.61, roughly 10% below consensus.
• ✅ Simply Wall St Valuation: Simply Wall St estimates the shares are trading 61.4% below fair value, flagged as undervalued.
• ✅ Recent Momentum: The 30 day return of about 4.5% shows recent positive momentum into this UAE health data deal.

There is only one way to know the right time to buy, sell or hold TELUS. Head to Simply Wall St’s
company report for the latest analysis of TELUS’s Fair Value.

Key Considerations

• 📊 The Abu Dhabi Health Data Services agreement adds an AI healthcare angle that sits alongside TELUS’s core telecom operations and existing digital health push.
• 📊 Keep an eye on any disclosed contract values, margin impact, and whether this UAE foothold leads to additional international health tech deals.
• ⚠️ With interest payments and the 8.62% dividend highlighted as pressure points, watch that expansion spending in health does not stretch the balance sheet further.

Dig Deeper

For the full picture including more risks and rewards, check out the
complete TELUS analysis. Alternatively, you can visit the
community page for TELUS to see how other investors believe this latest news will impact the company’s narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]